Business Context and Reporting Period
This Form 8-K Current Report was filed by Xcyte Therapies, Inc. on October 7, 2004. The filing discloses the entry into material definitive agreements regarding the company's Xcellerate Technology. Note: The request metadata lists "Bio Green Med Solution, Inc.", but the filing text explicitly identifies the registrant as Xcyte Therapies, Inc.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on contractual amendments rather than financial performance data.
Material Changes
On October 7, 2004, the Company executed two amendments to its existing Services Agreement with Lonza Biologics PLC (originally dated June 6, 2000):
- Amendment No. 5: Lonza will provide process analyses and services related to antibody manufacturing for Xcellerate Technology.
- Amendment No. 7: Lonza will provide process analyses and services related to antibody manufacturing for Xcellerate Technology.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or specific risk factors beyond the standard disclosure of the agreements. Certain information within the attached exhibits (Amendments No. 5 and No. 7) has been omitted and filed separately under a confidential treatment request.
Investor Verification Checklist
- Verify the specific financial terms and obligations within the omitted portions of Amendments No. 5 and No. 7.
- Confirm the impact of these manufacturing services on the timeline for Xcellerate Technology commercialization.
- Review the full text of the original June 6, 2000 Services Agreement to understand the baseline terms being amended.